title: [FGF/FGFR blockade: New insights in endometrial cancer].
authors.affiliation: Institut Gustave-Roussy, département d'oncologie médicale, 114, rue Édouard-Vaillant, 94800 Villejuif, France.
authors.forename: Ronan
authors.initials: R
authors.lastname: Flippot
authors.affiliation: Hôpital Louis-Pasteur, service d'oncologie et d'hématologie, 28630 Chartres-Le-Coudray, France. Electronic address: svignot@ch-chartres.fr.
authors.forename: Stéphane
authors.initials: S
authors.lastname: Vignot
mesh_terms: D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000235:genetics; D005260:Female; D005346:Fibroblast Growth Factors / Q000037:antagonists & inhibitors; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*; D015363:Quinolones / Q000009:adverse effects / Q000627:therapeutic use*; D017468:Receptors, Fibroblast Growth Factor / Q000037:antagonists & inhibitors* / Q000235:genetics
chemical_list: C500007:4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one; D001562:Benzimidazoles; D015363:Quinolones; D017468:Receptors, Fibroblast Growth Factor; D005346:Fibroblast Growth Factors
keywords: Cancer de l’endomètre; Endometrial cancer; FGF receptor; Molecular targeted therapy; Récepteur au FGF; Thérapie moléculaire ciblée